Affiliation:
1. College of Pharmacy, University of Illinois, Chicago, IL 60612, USA
Abstract
Non-invasive drug delivery across the blood–brain barrier (BBB) represents a significant advancement in treating neurological diseases. The BBB is a tightly packed layer of endothelial cells that shields the brain from harmful substances in the blood, allowing necessary nutrients to pass through. It is a highly selective barrier, which poses a challenge to delivering therapeutic agents into the brain. Several non-invasive procedures and devices have been developed or are currently being investigated to enhance drug delivery across the BBB. This paper presents a review and a prospective analysis of the art and science that address pharmacology, technology, delivery systems, regulatory approval, ethical concerns, and future possibilities.
Reference186 articles.
1. Gazzaniga, M.S., Ivry, R.B., and Mangun, G.R. (2018). Cognitive Neuroscience: The Biology of the Mind, Norton & Company.
2. Bear, M.F., Connors, B.W., and Paradiso, M.A. (2016). Neuroscience: Exploring the Brain, Wolters Kluwer Health.
3. Dynamics of CNS barriers: Evolution, differentiation, and modulation;Abbott;Cell. Mol. Neurobiol.,2005
4. The blood-brain barrier: Bottleneck in brain drug development;Pardridge;NeuroRx,2005
5. Daneman, R., and Prat, A. (2015). The blood–brain barrier. Cold Spring Harb. Perspect. Biol., 7.